In the Spotlight
African Postdoctoral Training Initiative fellow looks forward to collaborating within NCI
Rania Labib, Ph.D., is a postdoctoral fellow in the NIH African Postdoctoral Training Initiative (APTI) working in the lab of Beverly Mock, Ph.D., Deputy Chief of the Laboratory of Cancer Biology and Genetics. As part of the fellowship, she will spend two years at NCI conducting initial experiments in Dr. Mock’s lab, where she hopes to make a difference in possible treatment options for children with Burkitt’s lymphoma.
Read More
Recap: Grand Rounds with Felicia Knaul, Ph.D.
Nearly 200 CCR staff attended a special Grand Rounds lecture this month featuring Felicia Knaul, Ph.D., an expert in palliative care. Dr. Knaul, a professor at the Leonard M. Miller School of Medicine and Director of the University of Miami Institute for Advanced Study of the Americas, discussed the unequal access to pain and palliative care around the world, particularly related to morphine for pain relief, and the critical importance of educating providers.The lecture, held February 1, was sponsored by CCR’s Women Scientist Advisors (WSAs).
Read More
Watch new Neuro-Oncology Branch video on NCI YouTube
The Neuro-Oncology Branch is comprised of an exceptional team of experts across scientific disciplines and medical specialties dedicated to developing new treatments for patients with brain and spine cancers using the latest technologies. Learn more about this department.
Read More
FDA grants orphan drug status to selumetinib for neurofibromatosis type 1 (NF1) treatment
The U.S. Food and Drug Administration granted orphan drug status in February to selumetinib for use in patients with the genetic disorder neurofibromatosis type 1 (NF1), who often develop tumors of the peripheral nervous system. Receiving orphan drug designation is a helpful step for selumetinib.
Read More